| Dr Mae Mae Andrea Yu-shih Mirabelli, MD | |
|
61 Zurko Farm Rd, Milford, CT 06461-3064 | |
| (917) 554-9579 | |
| Not Available |
| Full Name | Dr Mae Mae Andrea Yu-shih Mirabelli |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 20 Years |
| Location | 61 Zurko Farm Rd, Milford, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992966519 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 237791 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baystate Medical Center | Springfield, MA | Hospital |
| Baystate Noble Hospital | Westfield, MA | Hospital |
| Baystate Wing Hospital | Palmer, MA | Hospital |
| Baystate Franklin Medical Center | Greenfield, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Radiology And Imaging Inc | 9234110479 | 50 |
| Radiology And Imaging Inc | 9234110479 | 50 |
News Archive
When bedbound intensive care patients are moved within a hospital, the single most common risk factor is nonfunctioning technology and equipment. These transfers, a well-known moment of risk, have been studied in a University of Gothenburg thesis.
ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
CANCER RESEARCH UK scientists have discovered that a single gene controls the oestrogen-fuelled growth of breast cancer cells, according to research published in Nature Genetics on Sunday.
Two common classes of blood pressure medications – angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) – are equally effective at controlling high blood pressure, according to a report released by the Agency for Healthcare Research and Quality, part of the U.S. Department of Health and Human Services.
› Verified 6 days ago
| Entity Name | Radiology & Imaging Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790731008 PECOS PAC ID: 9234110479 Enrollment ID: O20040525001128 |
News Archive
When bedbound intensive care patients are moved within a hospital, the single most common risk factor is nonfunctioning technology and equipment. These transfers, a well-known moment of risk, have been studied in a University of Gothenburg thesis.
ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
CANCER RESEARCH UK scientists have discovered that a single gene controls the oestrogen-fuelled growth of breast cancer cells, according to research published in Nature Genetics on Sunday.
Two common classes of blood pressure medications – angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) – are equally effective at controlling high blood pressure, according to a report released by the Agency for Healthcare Research and Quality, part of the U.S. Department of Health and Human Services.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mae Mae Andrea Yu-shih Mirabelli, MD 61 Zurko Farm Rd, Milford, CT 06461-3064 Ph: (917) 554-9579 | Dr Mae Mae Andrea Yu-shih Mirabelli, MD 61 Zurko Farm Rd, Milford, CT 06461-3064 Ph: (917) 554-9579 |
News Archive
When bedbound intensive care patients are moved within a hospital, the single most common risk factor is nonfunctioning technology and equipment. These transfers, a well-known moment of risk, have been studied in a University of Gothenburg thesis.
ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.
Sunesis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). Sunesis is currently conducting two Phase 2 clinical trials of voreloxin in AML: a single-agent study, known as REVEAL-1, of voreloxin in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy and a study evaluating voreloxin in combination with cytarabine in relapsed/refractory AML.
CANCER RESEARCH UK scientists have discovered that a single gene controls the oestrogen-fuelled growth of breast cancer cells, according to research published in Nature Genetics on Sunday.
Two common classes of blood pressure medications – angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) – are equally effective at controlling high blood pressure, according to a report released by the Agency for Healthcare Research and Quality, part of the U.S. Department of Health and Human Services.
› Verified 6 days ago
Dr. Eric A Ragaza, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 30 Commerce Park, Milford, CT 06460 Phone: 203-878-2341 Fax: 203-878-3429 | |
Dr. Paul S Davis, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 30 Commerce Park, Milford, CT 06460 Phone: 203-878-2341 Fax: 203-878-3429 | |
Dr. Vito E Errico, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 30 Commerce Park, Milford, CT 06460 Phone: 203-878-2341 Fax: 203-878-3429 |